142 related articles for article (PubMed ID: 37466447)
1. Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis.
Woode ME; Wong K; Reid CM; Stowasser M; Russell G; Gwini S; Young MJ; Fuller PJ; Yang J; Chen G
J Hypertens; 2023 Oct; 41(10):1615-1625. PubMed ID: 37466447
[TBL] [Abstract][Full Text] [Related]
2. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.
Chomsky-Higgins Menut K; Pearlstein SS; Conroy PC; Roman SA; Shen WT; Gosnell J; Sosa JA; Duh QY; Suh I
Surgery; 2022 Jan; 171(1):96-103. PubMed ID: 34238603
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of the Diagnosis and Treatment of Primary Aldosteronism in Japan.
Sato M; Morimoto R; Seiji K; Iwakura Y; Ono Y; Kudo M; Satoh F; Ito S; Ishibashi T; Takase K
Horm Metab Res; 2015 Oct; 47(11):826-32. PubMed ID: 26305168
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of screening for primary aldosteronism in China.
Li N; Huang J; Zheng B; Cai H; Liu M; Liu L
Clin Endocrinol (Oxf); 2021 Sep; 95(3):414-422. PubMed ID: 33837588
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.
Loh KC; Koay ES; Khaw MC; Emmanuel SC; Young WF
J Clin Endocrinol Metab; 2000 Aug; 85(8):2854-9. PubMed ID: 10946893
[TBL] [Abstract][Full Text] [Related]
8. Primary aldosteronism: an update on screening, diagnosis and treatment.
Rossi GP; Pessina AC; Heagerty AM
J Hypertens; 2008 Apr; 26(4):613-21. PubMed ID: 18327065
[TBL] [Abstract][Full Text] [Related]
9. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.
Stowasser M; Gordon RD; Gunasekera TG; Cowley DC; Ward G; Archibald C; Smithers BM
J Hypertens; 2003 Nov; 21(11):2149-57. PubMed ID: 14597859
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
[TBL] [Abstract][Full Text] [Related]
13. [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].
Chen SX; Du YL; Zhang J; Gong YC; Hu YR; Chu SL; He QB; Song YY; Zhu DL
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):868-72. PubMed ID: 17217708
[TBL] [Abstract][Full Text] [Related]
14. Screening for primary aldosteronism is underutilised in patients with chronic kidney disease.
Chauhan K; Schachna E; Libianto R; Ryan J; Hutton H; Fuller PJ; Wilson S; Kerr PG; Yang J
J Nephrol; 2022 Jul; 35(6):1667-1677. PubMed ID: 35195879
[TBL] [Abstract][Full Text] [Related]
15. Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration.
Baron S; Amar L; Faucon AL; Blanchard A; Baffalie L; Faucard C; Travers S; Pagny JY; Azizi M; Houillier P
J Hypertens; 2018 Jul; 36(7):1592-1601. PubMed ID: 29677048
[TBL] [Abstract][Full Text] [Related]
16. Who needs to be screened for primary aldosteronism?
Huang WC; Liu FH; Cheng HM; Tsai YC; Huang YT; Lai TS; Lin YH; Wu VC; Kao HL; Jia-Yin Hou C; Wu KD; Chen ST; Er LK
J Formos Med Assoc; 2024 Mar; 123 Suppl 2():S82-S90. PubMed ID: 37633770
[TBL] [Abstract][Full Text] [Related]
17. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management.
Minami HR; Itoga NK; George EL; Garcia-Toca M
J Vasc Surg; 2021 Dec; 74(6):2030-2039.e2. PubMed ID: 34175383
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study.
Kaur G; Chauhan AS; Prinja S; Teerawattananon Y; Muniyandi M; Rastogi A; Jyani G; Nagarajan K; Lakshmi P; Gupta A; Selvam JM; Bhansali A; Jain S
Lancet Public Health; 2022 Jan; 7(1):e65-e73. PubMed ID: 34774219
[TBL] [Abstract][Full Text] [Related]
20. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
Weiner ID
Semin Nephrol; 2013 May; 33(3):265-76. PubMed ID: 23953804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
